Schering-Plough Temodar Gets Priority Review For First-Line Glioma
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Schering-Plough’s brain tumor therapy Temodar will receive a priority review for first-line treatment of newly diagnosed, high-grade gliomas, the firm announced Oct. 29.